Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029376 | 0.90 | TP53 (0.34) | TP53PRKCA | |
| SCHEMBL10029381 | 0.81 | PRKCA (0.32) | TP53PRKCA | |
| SCHEMBL10029378 | 0.70 | TP53 (0.42) | TP53MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL13138169 | 0.63 | TP53 (0.39) | TP53MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL125808 | 0.63 | — | — | |
| SCHEMBL12156955 | 0.61 | TP53 (0.40) | TP53MEN1KMT2AMAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL30807127 | 0.61 | TSHR (0.57) | MEN1KMT2AMAPTLMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL30288135 | 0.61 | TSHR (0.57) | MEN1KMT2AMAPTLMNAL3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL9515995 | 0.61 | TSHR (0.57) | MEN1KMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL19281387 | 0.61 | TSHR (0.58) | KMT2ALMNAL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140343039-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | ROBIN JEAN-PIERRE (CH) | 2014-11-20 | — | — | US | disclosed |
| US-20140343039-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | ROBIN JEAN-PIERRE (CH) | 2014-11-20 | — | — | US | disclosed |
| US-20120022250-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | ROBIN JEAN-PIERRE (CH) | 2012-01-26 | — | — | US | disclosed |
| US-20120022250-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | ROBIN JEAN-PIERRE (CH) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022250-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | CHRM1, OPRM1, CHRM2 | TP53 4881/4885PRKCA 4497/4885MEN1 3409/4885 |
| US-20140343039-A1 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS | CFH, C5, CHRM1 | TP53 4881/4885PRKCA 3547/4885MEN1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.